Assessment of adverse effects and applicability - Two areas not (yet) covered adequately in Cochrane reports

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen

Volumn 102, Issue 8, 2008, Pages 497-502

  Gartlehner, Gerald ^a  

^a DANUBE UNIVERSITY KREMS   (Austria)

Author keywords

Adverse effects; Applicability; Cochrane reports; External validity; Generalizability; Harms

Indexed keywords

EID: 58149337575     PISSN: 18659217     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.zefq.2008.08.028     Document Type: Article

References (40)

1. Ezzo J, Bausell B, Moerman DE, Berman B, Hadhazy V. Reviewing the reviews. How strong is the evidence? How clear are the conclusions? Int J Technol Assess Health Care 2001 Fall; 17(4):457-66.
2. Hartling L, McAlister FA, Rowe BH, Ezekowitz J, Friesen C, Klassen TP. Challenges in systematic reviews of therapeutic devices and procedures. Ann Intern Med 2005: 142(12 Pt 2): 1100-11.
3. Santaguida PL, Helfand M, Raina P. Challenges in systematic reviews that evaluate drug efficacy or effectiveness. Ann Intern Med 2005:142(12 Pt 2):1066-72.
4. Chou R, Helfand M. Challenges in systematic reviews that assess treatment harms. Ann Intern Med 2005; 142(12 Pt 2): 1090-9.
5. Cuervo LG, Clarke M. Balancing benefits and harms in health care. BMJ 2003; 327(7406):65-6.
6. Cuervo LG. The road to health care. BMJ 3.07.2004:329:1-2.
7. Ernst E, Pittler MH. Assessment of therapeutic safety in systematic reviews: literature review. BMJ 2001;323(7312):546.
8. Papanikoiaou PN, Ioannidis JP. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. Am J Med 2004;117(8):582-9.
9. Scholten RJ, Clarke M, Hetherington J, The Cochrane Collaboration. Eur J Clin Nutr 2005;59(Suppl. 1):S 147-9 discussion S95-6.
10. Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared with industry supported meta-analyses and other metaanalyses of the same drugs: systematic review. BMJ 2006;333(7572):782.
11. Lang A, Edwards N, Fleiszer A. Empty systematic reviews: hidden perils and lessons learned. J Clin Epidemiol 2007 Jun; 60(6): 595-7.
12. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004;57(5):616-21.
13. Papanikolaou PN, Christidi GD, loannidis JP. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 2006 Feb 28; 174(5):635-41.
14. Ioannidis JP, Contopoulos-loannidis DG. Reporting of safety data from randomised trials. Lancet 1998:352(9142): 1752-3.
15. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285(4):437-43.
16. Ray WA. Population-Based Studies of Adverse Drug Effects. N Engl J Med 23.10.2003;349(17):1592-4.
17. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ 2006 Feb 28;174(5): 645-6.
18. Stricker BH, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ 2004 Jul 3;329(7456):44-7.
19. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004 Apr 24;363(9418):1341-5.
20. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141(10):781-8.
21. Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, et al. Comparative Effectiveness of Second-generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness Review No. 7-EHC007-EF. (Prepared by RTI-UNC under Contract No. 290-02-0016, TO #7.) Rockville, MD: Agency for Healthcare Research and Quality. 2007: Available at: 〈effectivehealthcare.ahrq.gov/reports/final.cfm〉.
22. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62(Suppl. 3):S10-21.
23. Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999 Dec; 11(4):205-15.
24. Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001 Jul;23(7): 1040-58.
25. Croft H, Settle Jr E, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999 Apr;21(4):643-58.
26. Donahue KE, Gartlehner G, Jonas DE, Lux U, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008 Jan 15; 148(2): 124-34.
27. Burdett S, Stewart LA, Tierney JF. Publication bias and meta-analyses: a practical example. Int J Technol Assess Health Care 2003; 19(1): 129-34.
28. UK Committee on Safety in Medicines. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. 2004 [updated 2004; cited]; Available from:(〈http://www.mhra.gov.uk/home/ groups/pl-p/documents/drugsafetymessage/con019472.pdf〉.
29. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004:363(9422): 1728-31.
30. Vandenbroucke JP. Benefits and narms of drug treatments. BMJ 2004 Jul 3; 329(7456):2-3.
31. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake Inhibitors: systematic review of randomised controlled trials, BMJ 2005 Feb 19;330(7488):396.
32. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and nonfatal self harm in first episode depression: nested case-control study. BMJ 2005 Feb 19;330(7488):389.
33. Asymptomatic Carotid Artherosclerosis Study Group. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995 May 10;273(18):1421-8.
34. Bond RRK, Rothwell PM. High morbidity due to endarterectomy for asymptomatic carotid stenosis. Cerebrovasc Dis 2003; 16(Suppl. 4):S65.
35. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002 Dec 7;325(7376):1332-3.
36. Malmlvaara A, Koes BW, Bouter LM, van Tulder MW. Applicability and clinical relevance of results in randomized controlled trials: the Cochrane review on exercise therapy for low back pain as an example. Spine 2006 Jun 1;31(13):1405-9.
37. Gross CP, Mallory R, Heiat A, Krumholz HM. Reporting the recruitment process in clinical trials: who are these patients and how did they get there? Ann Intern Med 2002; 137(1): 10-6.
38. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet 2005; 365(9453):82-93.
39. Godwin M, Ruhland L, Casson I, MacDonald S, Delva D, Birtwhistle R, et al. Pragmatic controlled clinical trials in primary care: the struggle between external and Internal validity. BMC Med Res Methodol 2003;3(1):28.
40. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 2006;59(10): 1040-8.